Clinical Trials Logo
  1. Home
  2. Ebola Virus Disease
  3. NCT04268966
  4. Details
NCT04268966 Clinical Trial

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Ebola Virus Disease Clinical Trial

— BCV EBOV  

Official title:
An Open-Label, Multicenter Study of the Safety and Tolerability of Brincidofovir (CMX001) for Post-Exposure Prophylaxis of Ebola Virus Disease

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04268966
Other study ID # CMX001-206
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date October 2014
Est. completion date December 2015

Study information
Verified date February 2020
Source Chimerix
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.

Description:

The primary objective of this study is to evaluate the safety and tolerability of BCV when administered for post-exposure prophylaxis of EVD

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Individuals have high-risk exposure to Ebola Virus based on CDC definitions

- Must be able to ingest, absorb and tolerate oral medication

- As appropriate, must be willing to use adequate methods of contraception during the study and at least 6 months after their last dose of BCV

Exclusion Criteria:

-

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Brincidofovir

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
Chimerix Food and Drug Administration (FDA)

Outcome
Type Measure Description Time frame Safety issue
Primary The primary objective of this study is to evaluate the safety and tolerability of BCV when administered for post-exposure prophylaxis of EVD 8 weeks
Secondary To assess the effect of BCV treatment on development of EVD in subjects through 21 days post-initiation of BCV therapy 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT00374309 - Experimental Vaccine for Prevention of Ebola Virus Infection Phase 1
Completed NCT03098862 - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed NCT02509494 - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Phase 3
Recruiting NCT06093646 - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda N/A
Completed NCT02495246 - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Phase 1
Completed NCT04906629 - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees Phase 1
Completed NCT05064956 - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Phase 2
Completed NCT02267109 - Phase 1 Trial of Ebola Vaccine in Mali Phase 1
Not yet recruiting NCT04822376 - Prophylaxis Vaccine Antibodies Ebola Phase 2
Recruiting NCT02333578 - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment N/A
Completed NCT02662855 - Efficacy of Favipiravir Against Severe Ebola Virus Disease Phase 2
Active, not recruiting NCT04152486 - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC Phase 3
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed NCT03161366 - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Phase 3
Completed NCT03140774 - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended NCT03462004 - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Phase 1
Active, not recruiting NCT02876328 - Partnership for Research on Ebola VACcinations Phase 2
Not yet recruiting NCT06126822 - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Phase 3
Not yet recruiting NCT05202288 - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Phase 2
Completed NCT02658331 - Evaluation of the FilmArray BioThreat-E Test N/A